Venture capital can play a role in bridging the gap between laboratory-based research and therapies developed by pharmaceutical companies for Alzheimer’s disease (AD). The Dementia Discovery Fund (DDF), was formed to provide funding and expertise to support companies developing novel treatments for dementia. Combining a focus on dementia with the rigour of for-profit venture capital investing greatly improves the odds of developing an effective therapeutic. Investment decisions are based on credible, proven science with the potential to deliver a drug, supported by excellent management teams. The DDF supports companies both financially and strategically drawing on the vast experience of its team of venture investors and scientific experts. Building syndicates with other investors de-risks individual investments, also providing the company with access to more capital and range of expertise. With a recent increase in the amount of available risk capital, coupled with a better understanding of the pathophysiology of AD and the use of precision medicine approaches, venture capital can have a greater impact on the discovery and development of a life-changing drug for patients with AD.